Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 16/20 | 0.68 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18790696 | 0.81 | CYP11B2 (0.61) | CYP11B2GSK3BDYRK1ALRRK2 | |
| SCHEMBL18790689 | 0.81 | CYP11B2 (0.44) | CYP11B2DYRK1ALRRK2 | |
| SCHEMBL18790685 | 0.81 | PIM2 (0.48) | CYP11B2DYRK1ALRRK2 | |
| SCHEMBL18790687 | 0.79 | CYP11B2 (0.49) | CYP11B2GSK3BDYRK1ALRRK2 | |
| SCHEMBL20514040 | 0.79 | CYP11B2 (0.43) | CYP11B2GSK3BDYRK1AWNT1 | |
| SCHEMBL22236835 | 0.73 | CYP11B2 (0.74) | CYP11B2 | |
| SCHEMBL22236836 | 0.73 | CYP11B2 (0.58) | CYP11B2ALDH1A1 | |
| SCHEMBL18790686 | 0.70 | PIM2 (0.57) | ALDH1A1 | |
| SCHEMBL20514060 | 0.70 | PIM2 (0.42) | CYP11B2GSK3BDYRK1A | |
| SCHEMBL22236779 | 0.68 | SIGMAR1 (0.63) | CYP11B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3381904-B1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-07-28 | — | — | EP | claimed |
| US-10717731-B2 | Nitrogen-containing aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-07-21 | — | — | US | claimed |
| US-20180312503-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-01 | — | — | US | claimed |
| EP-3381904-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-10-03 | — | — | EP | claimed |
| EP-3381904-B1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-07-28 | — | — | EP | disclosed |
| US-10717731-B2 | Nitrogen-containing aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-07-21 | — | — | US | disclosed |
| US-20180312503-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-01 | — | — | US | disclosed |
| EP-3381904-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717731-B2 | Nitrogen-containing aromatic heterocyclic compound | REN, NR3C2, NR5A1 | CYP11B2 8/4885GSK3B 2920/4885DYRK1A 4772/4885 |
| US-20180312503-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | REN, NR3C2, NR5A1 | CYP11B2 8/4885GSK3B 2778/4885DYRK1A 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.